ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
FTSE 100
8,433.76
0.63%
Dow Jones
39,512.84
0.32%
Gold vs US Dollar
2,360.48
0.00%
Brent Oil
82.585
0.00%
Bitcoin
61,176.01
0.62%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Castle Biosciences Inc (CSTL)

  7. Castle Biosciences Inc (CSTL) News

Castle Biosciences (CSTL)

Castle Biosciences Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CSTL
DateTimeSourceHeadlineSymbolCompany
10/05/202420:14Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CSTLCastle Biosciences Inc
10/05/202412:00Business WireCastle Biosciences’ IDgenetix® Test Receives 2024 MedTech Breakthrough Award for “Best Overall Mental Health Solution”NASDAQ:CSTLCastle Biosciences Inc
08/05/202421:30Business WireLargest Prospective Study to Date Further Supports Performance of DecisionDx®-UM for Metastatic Risk Stratification in Uveal Melanoma and Utility of PRAME Biomarker for Refining Risk When Considered with DecisionDx-UM Class ResultNASDAQ:CSTLCastle Biosciences Inc
03/05/202412:00Business WireDecisionDx®-SCC Significantly Improves Prediction Accuracy of Metastatic Events after Mohs Surgery in New Study of Patients with High-Risk Cutaneous Squamous Cell Carcinoma Tumors of the Head and NeckNASDAQ:CSTLCastle Biosciences Inc
02/05/202421:05Business WireCastle Biosciences Reports First Quarter 2024 ResultsNASDAQ:CSTLCastle Biosciences Inc
30/04/202421:30Business WireCastle Biosciences Kicks off Skin Cancer Awareness Month with a Ribbon Cutting to Celebrate the City of Friendswood’s Designation as a Sun Safe Leadership Model City by IMPACT MelanomaNASDAQ:CSTLCastle Biosciences Inc
11/04/202412:00Business WireCastle Biosciences to Release First Quarter 2024 Financial Results and Host Conference Call on Thursday, May 2, 2024NASDAQ:CSTLCastle Biosciences Inc
10/04/202422:00Business WireCastle Biosciences Celebrates Esophageal Cancer Awareness Month through Advocacy and Educational CollaborationsNASDAQ:CSTLCastle Biosciences Inc
10/04/202412:00Business WireCastle Biosciences’ Chief Financial Officer Frank Stokes Recognized as a Top CFO of Houston for Second Consecutive YearNASDAQ:CSTLCastle Biosciences Inc
04/04/202421:30Business WirePresentations at EADO Highlight Potential Impact of Castle Biosciences’ DecisionDx®-Melanoma and DecisionDx®-SCC Tests on the Management of Patients with Skin CancerNASDAQ:CSTLCastle Biosciences Inc
02/04/202412:00Business WireCastle Biosciences to Present at the 23rd Annual Needham Virtual Healthcare ConferenceNASDAQ:CSTLCastle Biosciences Inc
27/03/202421:00Business WireCastle Biosciences Announces Updates to its Board of DirectorsNASDAQ:CSTLCastle Biosciences Inc
25/03/202411:00Business WireCastle Biosciences Earns a Top Workplaces USA Award for the Third Consecutive YearNASDAQ:CSTLCastle Biosciences Inc
22/03/202420:30Business WireLong-term Outcomes Data Shared at SSO 2024 Show That Patients with a Low-Risk DecisionDx®-Melanoma Test Result Were Recurrence Free at Three Years, Including Those Who Utilized the Test to Help Guide the Decision to Avoid an SLNBNASDAQ:CSTLCastle Biosciences Inc
19/03/202411:00Business WireLeading Squamous Cell Carcinoma Practitioners Publish Consensus Guidelines Integrating DecisionDx®-SCC into a Clinical Workflow to Improve Decision-Making Regarding the Use of Adjuvant Radiation TherapyNASDAQ:CSTLCastle Biosciences Inc
15/03/202420:30Business WireNew Study Shows that the Drug-Drug Interactions and Lifestyle Factors Provided by Castle Biosciences’ IDgenetix® Test Significantly Improve Medication Recommendations Over Drug-Gene Interactions Alone for Patients 65 and OlderNASDAQ:CSTLCastle Biosciences Inc
12/03/202411:00Business WireCastle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor ForumNASDAQ:CSTLCastle Biosciences Inc
08/03/202421:30Business WireCastle Biosciences to Present New Data Highlighting the Clinical Value of its Dermatologic Tests for Patients with Skin Cancer at the 2024 American Academy of Dermatology (AAD) Annual MeetingNASDAQ:CSTLCastle Biosciences Inc
07/03/202412:00Business WireIn Novel Cohort, New Data Confirms DecisionDx®-SCC Provides Significant, Independent and Clinically Actionable Risk-Stratification of Patients, Including in Various High-Risk SubgroupsNASDAQ:CSTLCastle Biosciences Inc
06/03/202423:07Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
06/03/202423:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
06/03/202423:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CSTLCastle Biosciences Inc
28/02/202422:15Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:CSTLCastle Biosciences Inc
28/02/202421:05Business WireCastle Biosciences Reports Fourth Quarter and Full-Year 2023 ResultsNASDAQ:CSTLCastle Biosciences Inc
26/02/202412:00Business WireStudy Finds DecisionDx®-Melanoma Significantly Improves the Risk Stratification of Patients with Stage I Melanoma Compared to American Joint Committee on Cancer 8th Edition StagingNASDAQ:CSTLCastle Biosciences Inc
07/02/202412:00Business WireCastle Biosciences to Release Fourth Quarter and Full-Year 2023 Financial Results and Host Conference Call on Wednesday, Feb. 28, 2024NASDAQ:CSTLCastle Biosciences Inc
18/01/202412:00Business WireNew Study Highlights Significant Potential Medicare Savings Through Use of Castle Biosciences’ DecisionDx®-SCC Test to Guide Adjuvant Radiation Therapy Decisions in Patients with Cutaneous Squamous Cell CarcinomaNASDAQ:CSTLCastle Biosciences Inc
14/01/202409:30Business WireCastle Biosciences Presents Data Supporting the Utility of Its Tests in the Clinical Care of Patients with Skin Cancers at the 2024 Winter Clinical Dermatology Conference - Hawaii®NASDAQ:CSTLCastle Biosciences Inc
09/01/202412:00Business WireCastle Biosciences’ Chief Operating Officer Kristen Oelschlager Selected Among the Top 25 Women Leaders in Biotechnology by The Healthcare Technology ReportNASDAQ:CSTLCastle Biosciences Inc
08/01/202412:04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CSTLCastle Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:CSTL

Your Recent History

COIN
NOOGBP
Delayed Upgrade Clock
    ADVFN Logo

    United Kingdom
    Company
    Business
    Popular
    Get The App

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved